NASDAQ$LFST
LifeStance Health Group Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
LifeStance reported a revenue increase of 20%, a net loss reduction, and raised full year 2024 expectations.
LifeStance Health Group reported a 20% increase in revenue to $312.3 million for Q2 2024. The company's net loss decreased from $45.5 million to $23.3 million. Adjusted EBITDA increased 103% to $28.6 million. The company is raising full year 2024 revenue expectations to $1.2 billion to $1.242 billion and expects positive Free Cash Flow.
- Revenue increased 20% to $312.3 million.
- The clinician base increased 14% to 6,984 clinicians.
- Second quarter visit volumes increased 15% to 2.0 million.
- Adjusted EBITDA increased 103% to $28.6 million.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$312M
Forward guidance
LifeStance is raising full year revenue to $1.2 billion to $1.242 billion; raising Center Margin to $363 million to $383 million; and raising Adjusted EBITDA to $90 million to $100 million. Additionally, the Company continues to expect to generate positive Free Cash Flow for the full year. For the third quarter of 2024, the Company expects total revenue of $290 million to $310 million, Center Margin of $83 million to $95 million, and Adjusted EBITDA of $15 million to $21 million.
Tailwinds
- Raising full year revenue guidance to $1.2 billion - $1.242 billion.
- Raising Center Margin guidance to $363 million - $383 million.
- Raising Adjusted EBITDA guidance to $90 million - $100 million.
- Reiterating expectations for positive Free Cash Flow for the full year.
- Expecting Q3 2024 revenue of $290 million - $310 million.
Headwinds
- Expecting Q3 2024 Center Margin of $83 million - $95 million.
- Expecting Q3 2024 Adjusted EBITDA of $15 million - $21 million.
- Uncertainty in achieving the raised guidance.
- Potential impact of external factors on financial performance.
- Dependence on successful execution of business strategies for achieving guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro